Mechanistic studies on metabolic interactions between gemfibrozil and statins

Journal of Pharmacology and Experimental Therapeutics

Volumn 301, Issue 3, 2002, Pages 1042-1051

  Prueksaritanont, Thomayant ^a   Zhao, Jamie J ^a   Ma, Bennett ^a   Roadcap, Brad A ^a   Tang, Cuyue ^a   Qiu, Yue ^a   Liu, Lida ^a   Lin, Jiunn H ^a   Pearson, Paul G ^a   Baillie, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DRUG METABOLITE; GEMFIBROZIL; GLUCURONIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOENZYME; SIMVASTATIN;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG OXIDATION; DRUG POTENCY; ENZYME MECHANISM; HUMAN; LIVER MICROSOME; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTILIPEMIC AGENTS; AREA UNDER CURVE; CATALYSIS; DOGS; DRUG INTERACTIONS; GEMFIBROZIL; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROLYSIS; ISOENZYMES; MICROSOMES, LIVER; OXIDATION-REDUCTION; SIMVASTATIN;

EID: 0036266987     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.301.3.1042     Document Type: Article

References (39)

1. Plasma concentrations of active simvastatin acid are increased by gemfibrozil
2. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters
3. Metabolism of cerivastatin by human liver microsomes in vitro: Characterization of primary metabolic pathways and cytochrome P450 isozymes involved
4. Biotransformation of cerivastatin in mice, rats and dogs in vivo
5. Metabolic disposition of simvastatin in patients with T-tube drainage
6. New insights into the pharmacodynamic and pharmacokinetic properties of statins
7. Rabbit serum paraoxonase 3 (PON3) is a high-density lipoprotein-associated lactonase and protects low-density lipoprotein against oxidation
8. Learning from the cerivastatin experience
9. Current and future treatment of hyperlipidemia: The role of statins
10. In vitro glucuronidation using human liver microsomes and the poreforming peptide alamethicin
11. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease
12. In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: Interactions with other drugs
13. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins)
14. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin
15. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
16. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
17. 14C]-atorvastatin in patients with T-tube drainage
18. Drug glucuronidation in clinical psychopharmacology
19. Current perspectives on statins
20. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
21. Clinical pharmacokinetics of cerivastatin
22. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
23. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
24. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
25. The metabolism of gemfibrozil
26. In vitro metabolism of simvastatin in humans: Identification of metabolizing enzymes and effect of the drug on hepatic P450s
27. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
28. Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization
29. Role of fibrates in the management of hypertriglyceridemia
30. Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions
31. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
32. Statin-fibrate combination therapy
33. Drug interactions with antiviral drugs
34. Glucuronidation of 3′-azido-3′-deoxythymidine (Zidovudine) by human liver microsomes: Relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid
35. Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes
36. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9
37. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: Erythromycin and ethinyl estradiol
38. Metabolic disposition studies of simvastatin, a cholesterol-lowering prodrug
39. Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography-tandem mass spectrometry